Fig 2.

Kaplan-Meier survival curves of (A) overall survival (OS) and (B) progression-free survival (PFS) of the four major intrinsic glioma subtypes (IGSs) to which the patients from the European Organisation for Research and Treatment of Cancer (EORTC) 26951 trial were assigned. Survival is depicted as time (years) since random assignment. The four IGSs were highly prognostic for both OS and PFS because patient prognosis was different for each IGS. Only two and eight samples were assigned to IGS-16 and IGS-22, respectively (not shown).